Literature DB >> 34382119

Prospective Evaluation of an Abbreviated Test Battery to Screen for Neurocognitive Impairment in HIV-Positive Military Members.

Brian K Agan1,2, Seung Hyun Won3,4, Anuradha Ganesan3,4,5, Bryan R Smith6, Camille Estupigan3,4, Ryan Maves3,7, Gregory Utz3,4,7, Hsing-Chuan Hsieh3,4, Edmund Tramont8, Avindra Nath6, Joseph Snow9.   

Abstract

Human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) affects around 20-50% of people living with HIV (PLWH). Although batteries of tests are used to identify neurocognitive impairment (NCI), they are long and difficult to perform during a routine clinic visit, thus impairing the ability to diagnose HAND. Therefore, a brief yet sensitive screening tool to identify NCI is necessary. This study prospectively evaluated an abbreviated screening battery with reported 86.5%/87.1% sensitivity/specificity, identified from a planned post-hoc analysis in a prior neurocognitive study among military PLWH. Adult HIV-positive military beneficiaries in the U.S. Military HIV Natural History Study, who agreed to undergo a comprehensive seven-domain neuropsychological battery (16 tests), and who completed an additional 20-min abbreviated battery (AB), comprised of four tests, prior to the full battery (FB) were included in this analysis. A group of 169 individuals completed both tests, of which 25.4% had a positive AB and 17.8% had NCI on FB (global deficit score ≥ 0.5). With the FB as the reference standard, the specificity for the AB was 79.9% (73.2-86.5), however the sensitivity was 50.0% (32.1-67.9). In those with NCI by FB but not AB, the most common impaired domains were executive function (73.3%) and memory (73.3%), both being domains not fully tested by the AB. An abbreviated HAND screening battery of four tests requiring approximately 20 min provided a relatively high level of specificity but lacked sensitivity for detection of NCI. Inclusion of additional domains or alternative scoring approaches may improve sensitivity but require further study. Continued efforts are needed to develop an effective brief screening test for HAND.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  HIV-associated neurocognitive disorder; Human immunodeficiency virus; Neurocognitive impairment; Screening

Mesh:

Year:  2021        PMID: 34382119      PMCID: PMC8446745          DOI: 10.1007/s10461-021-03341-6

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  26 in total

Review 1.  A comprehensive review of the Paced Auditory Serial Addition Test (PASAT).

Authors:  Tom N Tombaugh
Journal:  Arch Clin Neuropsychol       Date:  2005-11-14       Impact factor: 2.813

2.  Action (verb naming) fluency as an executive function measure: convergent and divergent evidence of validity.

Authors:  A L Piatt; J A Fields; A M Paolo; A I Tröster
Journal:  Neuropsychologia       Date:  1999-12       Impact factor: 3.139

Review 3.  HIV-associated neurocognitive disorder.

Authors:  David B Clifford; Beau M Ances
Journal:  Lancet Infect Dis       Date:  2013-11       Impact factor: 25.071

4.  HIV-associated executive dysfunction in the era of modern antiretroviral therapy: A systematic review and meta-analysis.

Authors:  Keenan A Walker; Gregory G Brown
Journal:  J Clin Exp Neuropsychol       Date:  2017-07-09       Impact factor: 2.475

5.  Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study.

Authors:  J C McArthur; D R Hoover; H Bacellar; E N Miller; B A Cohen; J T Becker; N M Graham; J H McArthur; O A Selnes; L P Jacobson
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

6.  Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons.

Authors:  Nancy F Crum-Cianflone; David J Moore; Scott Letendre; Mollie Poehlman Roediger; Lynn Eberly; Amy Weintrob; Anuradha Ganesan; Erica Johnson; Raechel Del Rosario; Brian K Agan; Braden R Hale
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

Review 7.  Changing clinical phenotypes of HIV-associated neurocognitive disorders.

Authors:  Ned Sacktor
Journal:  J Neurovirol       Date:  2017-07-27       Impact factor: 3.739

8.  HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.

Authors:  Robert K Heaton; Donald R Franklin; Ronald J Ellis; J Allen McCutchan; Scott L Letendre; Shannon Leblanc; Stephanie H Corkran; Nichole A Duarte; David B Clifford; Steven P Woods; Ann C Collier; Christina M Marra; Susan Morgello; Monica Rivera Mindt; Michael J Taylor; Thomas D Marcotte; J Hampton Atkinson; Tanya Wolfson; Benjamin B Gelman; Justin C McArthur; David M Simpson; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Terry L Jernigan; Joseph Wong; Igor Grant
Journal:  J Neurovirol       Date:  2010-12-21       Impact factor: 2.643

Review 9.  Validity of cognitive screens for HIV-associated neurocognitive disorder: a systematic review and an informed screen selection guide.

Authors:  Jody Kamminga; Lucette A Cysique; Grace Lu; Jennifer Batchelor; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2013-12       Impact factor: 5.071

10.  Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic.

Authors:  Victor Marin-Webb; Heiko Jessen; Ute Kopp; Arne B Jessen; Katrin Hahn
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.